613 related articles for article (PubMed ID: 19502264)
1. Efficacy and safety of infliximab in active SLE: a pilot study.
Uppal SS; Hayat SJ; Raghupathy R
Lupus; 2009 Jul; 18(8):690-7. PubMed ID: 19502264
[TBL] [Abstract][Full Text] [Related]
2. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Aringer M; Graninger WB; Steiner G; Smolen JS
Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
[TBL] [Abstract][Full Text] [Related]
4. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
[TBL] [Abstract][Full Text] [Related]
5. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.
Aringer M; Steiner G; Graninger WB; Höfler E; Steiner CW; Smolen JS
Arthritis Rheum; 2007 Jan; 56(1):274-9. PubMed ID: 17195231
[TBL] [Abstract][Full Text] [Related]
6. Differences in tumor necrosis factor-alpha soluble receptor serum concentrations between patients with Henoch-Schönlein purpura and pediatric systemic lupus erythematosus: pathogenetic implications.
Gattorno M; Picco P; Barbano G; Stalla F; Sormani MP; Buoncompagni A; Gusmano R; Borrone C; Pistoia V
J Rheumatol; 1998 Feb; 25(2):361-5. PubMed ID: 9489835
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor induced adhesion molecule serum concentrations in Henoch-Schönlein purpura and pediatric systemic lupus erythematosus.
Gattorno M; Vignola S; Barbano G; Sormani MP; Sabatini F; Buoncompagni A; Picco P; Pistoia V
J Rheumatol; 2000 Sep; 27(9):2251-5. PubMed ID: 10990243
[TBL] [Abstract][Full Text] [Related]
8. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial.
Muller S; Monneaux F; Schall N; Rashkov RK; Oparanov BA; Wiesel P; Geiger JM; Zimmer R
Arthritis Rheum; 2008 Dec; 58(12):3873-83. PubMed ID: 19035498
[TBL] [Abstract][Full Text] [Related]
9. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
Mok CC; Ho LY; Cheung MY; Yu KL; To CH
Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B
Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations.
Yajima N; Kasama T; Isozaki T; Odai T; Matsunawa M; Negishi M; Ide H; Kameoka Y; Hirohata S; Adachi M
Arthritis Rheum; 2005 Jun; 52(6):1670-5. PubMed ID: 15934075
[TBL] [Abstract][Full Text] [Related]
12. The effect of menopause on disease activity in systemic lupus erythematosus.
Urowitz MB; Ibañez D; Jerome D; Gladman DD
J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
[TBL] [Abstract][Full Text] [Related]
13. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.
Wais T; Fierz W; Stoll T; Villiger PM
J Rheumatol; 2003 Oct; 30(10):2133-9. PubMed ID: 14528506
[TBL] [Abstract][Full Text] [Related]
14. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics.
Omdal R; Mellgren SI; Koldingsnes W; Jacobsen EA; Husby G
J Rheumatol; 2002 Mar; 29(3):482-6. PubMed ID: 11908560
[TBL] [Abstract][Full Text] [Related]
15. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.
Denton CP; Engelhart M; Tvede N; Wilson H; Khan K; Shiwen X; Carreira PE; Diaz Gonzalez F; Black CM; van den Hoogen FH
Ann Rheum Dis; 2009 Sep; 68(9):1433-9. PubMed ID: 18782794
[TBL] [Abstract][Full Text] [Related]
16. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
[TBL] [Abstract][Full Text] [Related]
17. Antibody clustering helps refine lupus prognosis.
Kessel A; Rosner I; Halasz K; Grushko G; Shoenfeld Y; Paran D; Toubi E
Semin Arthritis Rheum; 2009 Aug; 39(1):66-70. PubMed ID: 18538829
[TBL] [Abstract][Full Text] [Related]
18. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.
Hanly JG; McCurdy G; Fougere L; Douglas JA; Thompson K
J Rheumatol; 2004 Nov; 31(11):2156-62. PubMed ID: 15517627
[TBL] [Abstract][Full Text] [Related]
19. Outcome measures to be used in clinical trials in systemic lupus erythematosus.
Strand V; Gladman D; Isenberg D; Petri M; Smolen J; Tugwell P
J Rheumatol; 1999 Feb; 26(2):490-7. PubMed ID: 9972993
[TBL] [Abstract][Full Text] [Related]
20. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.
Kalunian KC; Davis JC; Merrill JT; Totoritis MC; Wofsy D;
Arthritis Rheum; 2002 Dec; 46(12):3251-8. PubMed ID: 12483729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
